Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
79862.400.5934%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

Dr Reddy's Laboratories Ltd

RDYNYSE
Trade with Public
Trade with Public
$11.97
-0.06-0.5%
At close: Sep 4, 5:00 PM EST
$11.97
N/A
After Hours: Sep 4, 4:34 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentDividendsCompareOptionsStock Report

Dr Reddy's Laboratories Analyst Price Targets

Wall Street analyst price targets and consensus rating for Dr Reddy's Laboratories (RDY).

Price Target Range — 5 Quarters

Analyst Consensus — 2 Analysts

2Buy
Consensus RatingOverweight# Analysts2Avg. Consensus PT$17Upside to Avg. PT+41.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jun 5, 2025HSBCDamayanti Kerai UpgradeHold→Buy$14→$17
Nov 6, 2024BarclaysBalaji PrasadMaintainedOverweight$17→$17
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HSBC Upgrades Dr Reddy's Laboratories to Buy, Raises Price Target to $16.9

HSBC analyst Damayanti Kerai upgrades Dr Reddy's Laboratories (NYSE:RDY) from Hold to Buy and raises the price target from $14.44 to $16.9.
Benzinga Newsdesk

Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline

Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs.
Vandana Singh

PRO
Barclays Maintains Overweight on Dr Reddy's Laboratories, Raises Price Target to $87

Barclays analyst Balaji Prasad maintains Dr Reddy's Laboratories (NYSE:RDY) with a Overweight and raises the price target from $81 to $87.
Benzinga Newsdesk

Dr. Reddy's to Acquire Haleon's Nicotine Addiction Drug

Dr.
Zacks

PRO
Barclays Maintains Overweight on Dr Reddy's Laboratories, Raises Price Target to $81

Barclays analyst Balaji Prasad maintains Dr Reddy's Laboratories (NYSE:RDY) with a Overweight and raises the price target from $80 to $81.
Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Dr Reddy's Laboratories, Raises Price Target to $80

Barclays analyst Balaji Prasad maintains Dr Reddy's Laboratories (NYSE:RDY) with a Overweight and raises the price target from $75 to $80.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved